New Delhi: Emcure Pharmaceuticals Limited has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) following an inspection of its formulations manufacturing facility in Sanand, Ahmedabad, Gujarat. The USFDA has classified the inspection status of the facility as Voluntary Action Indicated (VAI), and the inspection has consequently been closed. The company referred to its earlier intimation dated May 16, 2026, concerning the USFDA inspection at the facility. The latest company disclosure confirms that the Establishment Inspection Report has now been received and that the regulatory inspection has been classified as VAI. The company’s disclosure specifically concerns the USFDA inspection of its Sanand formulations facility and the subsequent receipt of the Establishment Inspection Report (EIR) from the USFDA.